Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

NCT03604198 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT03604198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03604198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
Lead sponsor
Corcept Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 7, 2018
Completion date
December 31, 2026
Enrollment
125 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

cushing syndrome